Cargando…
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality
BACKGROUND: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. METHODS: This was the final day 28 comparat...
Autores principales: | Olender, Susan A, Walunas, Theresa L, Martinez, Esteban, Perez, Katherine K, Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G, De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M, Lye, David Chien, Gottlieb, Robert L, Haubrich, Richard H, Chokkalingam, Anand P, Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M, Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O, Bernardino, Jose I, Boffito, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244650/ https://www.ncbi.nlm.nih.gov/pubmed/34282406 http://dx.doi.org/10.1093/ofid/ofab278 |
Ejemplares similares
-
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
por: Olender, Susan A, et al.
Publicado: (2020) -
73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020) -
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
por: Goldman, Jason D., et al.
Publicado: (2020) -
Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States
por: Chokkalingam, Anand P., et al.
Publicado: (2022) -
72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)